Causes of Anemia in Cancer Patients

  • Nedjeljka Baldass


Anemia frequently is associated with cancer or its treatment. Anemia may manifest itself in symptoms that include fatigue, shortness of breath, chest pain, weakness, loss of appetite, and headache. Even mild to moderate anemia may cause fatigue at rest, and may deleteriously affect a cancer patient’s ability to perform normal daily activities. Along with functional impairment, anemic cancer patients may suffer a decline in their sense of well-being. The quality-of-life domains of exercise tolerance, work capability, social interaction, and leisure enjoyment may each be affected by anemia symptoms.1. Left untreated, anemia in cancer patients may become severe, necessitating red blood cell (RBC) transfussion.


Serum Ferritin Level Medical Economic Small Cell Lung Cancer Patient Functional Iron Deficiency Nitor Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Yellen et al. J Symptom Pain Manage 1997; (13): 2Google Scholar
  2. 2.
    Spivak JL. Sem Oncol 1994; 21 (suppl 3): 3s–8sGoogle Scholar
  3. 3.
    Abels et al. In: Murphy, Blood Cell Growth Factors: Their Present and Future Use in Hematology and Oncology. Dayton, Ohio: Alpha Med Press 1991; 121–141Google Scholar
  4. 4.
    Krantz SB. Am J Med Sci 1994; 307: 353–359PubMedCrossRefGoogle Scholar
  5. 5.
    Pincus et al. Am J Med 1990; 89:161–168PubMedCrossRefGoogle Scholar
  6. 6.
    Doweiko et al. Oncology 1991; 5: 31–44PubMedGoogle Scholar
  7. 7.
    Miller et al. N Engl J Med 1990; 322: 1689–1692PubMedCrossRefGoogle Scholar
  8. 8.
    Schilling RF. Ann Int Med 1991; 115: 572–573PubMedGoogle Scholar
  9. 9.
    DeRienzo et al. Tex Med 1990; 86: 80–83PubMedGoogle Scholar
  10. 10.
    Krantz SB. Blood 1991; 77: 414–434Google Scholar
  11. 11.
    Brunn HF. In: Harrison’s Principles of Internal Medicine, 13th ed. New York, 1994; 1717–1721Google Scholar
  12. 12.
    Varat et al. Am Heart J 1972; 83: 415–426PubMedCrossRefGoogle Scholar
  13. 13.
    Bunn et al. Harrisons’s Principles of Internal Medicine, 13th ed. New York, 1994; 313–317Google Scholar
  14. 14.
    Jain et al. Med Clin North Am 1992; 76: 727–744PubMedGoogle Scholar
  15. 15.
    Graettinger et al. Ann Int Med 1963; 58: 617–626PubMedGoogle Scholar
  16. 16.
    Skillings et al. Am J Clin Oncol 1993; 16: 22–25PubMedCrossRefGoogle Scholar
  17. 17.
    Patterson et al. Sem Oncol 1992; 19: 521–528Google Scholar
  18. 18.
    Paraplatin prescribing information. Medical Economics 1997; 713–717Google Scholar
  19. 19.
    Taxol prescribing information. Medical Economics Co 1997; 723–727Google Scholar
  20. 20.
    Taxotere prescribing information. Medical Economics Co 1997; 2204–2207Google Scholar
  21. 21.
    Gemzar prescribing information. Medical Economics Co 1997; 1482–1485Google Scholar
  22. 22.
    Hycamtin prescribing information. Medical Economics Co 1997; 2665–2667Google Scholar
  23. 23.
    Camptosar prescribing information. Medical Economics Co 1997; 2060–2064Google Scholar
  24. 24.
    Abels et al. Risk of transfusion in small cell lung cancer patients receiving chemotherapy. Blood 1994; 84: 664A, Abstract 2642Google Scholar
  25. 25.
    Glaspy et al. J Clin Oncol 1997; 15 (3): 1218–1234PubMedGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2001

Authors and Affiliations

  • Nedjeljka Baldass

There are no affiliations available

Personalised recommendations